Skip to main content
. 2020 Aug 15;17(3):707–725. doi: 10.20892/j.issn.2095-3941.2020.0056

Figure 1.

Figure 1

High expression of SHP2 is associated with poor prognosis in patients with breast cancer. (A, B) The overall survival rate in patients with elevated SHP2 expression was significantly poorer than that in patients with low SHP2 expression, on the basis of the TCGA and GSE20685 databases (P < 0.001 and P = 0.043, respectively). (C, D) The relapse-free survival rate in patients with elevated SHP2 expression was significantly poorer than that in patients with low SHP2 expression, on the basis of the GSE21653 and the GSE2034 databases (P = 0.039 and P = 0.035, respectively). (E) The expression of SHP2 in breast cancer tissue was detected via IHC staining. The expression of SHP2 was scored according to the stained area and staining intensity, and divided into 2 groups with high and low SHP2 expression.